CASP3 and prostate carcinoma: Treatment of the androgen-independent human prostate cancer cells PC-3 with doxazosin resulted in a strong caspase-3 activation within 24 h, whereas tamsulosin, a sulphonamide-based α1-adrenoceptor antagonist, had no significant apoptotic effect against prostate cancer cells.